Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
First Claim
1. A method of treating a subject having a having, determined to have, or suspected of having a neuroinflammatory or neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to SEMA4D, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 14, 15, and 16, respectively, and wherein the binding to SEMA4D acts to alleviate symptoms associated with the disorder.
3 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
-
Citations
15 Claims
- 1. A method of treating a subject having a having, determined to have, or suspected of having a neuroinflammatory or neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to SEMA4D, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 14, 15, and 16, respectively, and wherein the binding to SEMA4D acts to alleviate symptoms associated with the disorder.
- 9. A method of protecting inhibitory neurons from degeneration in early Alzheimer'"'"'s disease, comprising administering to a subject having, determined to have, or suspected of having early Alzheimer'"'"'s disease an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to SEMA4D, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 14, 15, and 16, respectively, and wherein the antibody or antigen-binding fragment thereof restores the number of somatostatin positive neurons, NYP-positive neurons, or both in the subject.
Specification